Scientific Resources

Our next-generation diagnostic assays have generated novel insights across a broad range of clinical applications.

Access our presentations, publications, and more to see how we’re unlocking the full potential of precision genomics.

Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel therapy in relapsed/refractory large B-cell lymphoma
June 20, 2025 | Poster
Safety and Efficacy of AZD0486, a CD19xCD3 T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 3, 2025 | Poster
Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab
June 3, 2025 | Poster
ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
June 3, 2025 | Poster
Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in NewlyDiagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA (NCT06693830)
June 3, 2025 | Poster
Prospective Validation of End-of-Treatment ctDNA-MRD by PhasED-Seq in 1L DLBCL Patients from a National Cohort
May 30, 2025 | Presentation